Morgan Stanley analyst Jeffrey Hung initiates coverage on $BioAge Labs (BIOA.US)$ with a buy rating, and sets the target price at $40.
According to TipRanks data, the analyst has a success rate of 59.7% and a total average return of 19.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs is a clinical-stage biotechnology firm concentrated on the progression of therapies targeting metabolic diseases. The company's primary candidate, azelaprag, is an orally administered, small molecule that stimulates the apelin receptor and is currently being developed to address obesity. There is an anticipation of a favorable risk/reward situation for the company's shares leading up to the STRIDES outcome, bolstered by azelaprag's oral administration, straightforward manufacturing, and substantial preclinical evidence that suggests a promising clinical profile in the treatment of obesity.
Initial findings suggest that BioAge Labs' azelaprag may facilitate weight loss when used alongside GLP-1s, and could also enhance body composition and the quality of weight loss. Early evidence points toward azelaprag's ability to promote weight reduction while simultaneously providing muscle benefits.
BioAge Labs is recognized as a clinical-stage biotech company with a focus on metabolic diseases. The lead drug, Azelaprag, is noted for its unique approach as an exercise mimetic in the treatment of obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
